Enrolment

Assessed for eligibility (N = 3558)

Excluded (N = 967)*

Randomized (N = 2591)

Randomization

Randomized to chemotherapy alone (N = 1290)
- Received allocated treatment (N = 1270)
- Did not receive allocated treatment
  - No study drug received (N = 18)
  - Received bevacizumab (N = 2)

Randomized to chemotherapy plus bevacizumab (N = 1301)
- Received allocated treatment (N = 1286)
- Did not receive allocated treatment
  - No study drug received (N = 14)
  - Received no bevacizumab (N = 1)

Analysis

Analyzed for efficacy (N = 1290)
Analyzed for safety (N = 1271)

Analyzed for efficacy (N = 1301)
Analyzed for safety (N = 1288)

Follow-up

Alive in follow-up/survival follow-up (N = 1001)
Lost to follow-up (N = 140)
Death (N = 149)

Alive in follow-up/survival follow-up (N = 1047)
Lost to follow-up (N = 110)
Death (N = 144)